New agents for the treatment of acute myeloid leukemia
- 30 June 2006
- journal article
- review article
- Published by Elsevier in Best Practice & Research Clinical Haematology
- Vol. 19 (2) , 311-320
- https://doi.org/10.1016/j.beha.2005.11.006
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Drug therapy for acute myeloid leukemiaBlood, 2005
- Phase I Study of Oblimersen Sodium, an Antisense to Bcl-2, in Untreated Older Patients With Acute Myeloid Leukemia: Pharmacokinetics, Pharmacodynamics, and Clinical ActivityJournal of Clinical Oncology, 2005
- Antileukemic activity of rapamycin in acute myeloid leukemiaBlood, 2005
- Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemiasBlood, 2005
- Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia:: A randomised phase II trial from HOVON, the Dutch–Belgian Haemato-Oncology Working Group for adultsLeukemia Research, 2004
- Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AMLBlood, 2004
- Mitoxantrone, Etoposide, and Cytarabine With or Without Valspodar in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome: A Phase III Trial (E2995)Journal of Clinical Oncology, 2004
- A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemiaBlood, 2003
- Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemiaBlood, 2003
- Comparison of ‘sequential’ versus ‘standard’ chemotherapy as re‐induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML‐R trialBritish Journal of Haematology, 2001